Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

Share Price is delayed by 15 minutes
Get Live Data
8.25    1.10 (14.86%)
Bid:
8.00
Ask:
8.50
Spread: 0.50 (6.25%)
Market Cap: £59.93m
POLB Live PriceLast checked at - London Stock Exchange

Intraday Poolbeg Pharma Share Chart

Form 8.5 (EPT/RI) - Poolbeg Pharma Plc

12 Feb 2025 10:52

Form 8.5 (EPT/RI) - Poolbeg Pharma Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Shore Capital Stockbrokers Ltd
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereePoolbeg Pharma Plc
(c) Name of the party to the offer with which exempt principal trader is connected:Poolbeg Pharma Plc
(d) Date dealing undertaken:11 February 2025
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?No

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid/receivedLowest price per unit paid/received
OrdinaryPurchases5,3615.082p5.082p
OrdinarySales55,3615.138p5.1p

(b) Derivatives transactions (other than option)

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercising

Class of relevant securityProduct description e.g. call optionNumber of securitiesExercise price per unit
    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
    

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure:12 February 2025
Contact name:Laura Parmenter
Telephone number:0207 647 8154

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
26th May 20267:00 amRNSPre-IND Meeting with the FDA for POLB 001
13th May 20267:00 amRNSPOLB 001 poster to be presented at EHA 2026
11th May 20267:00 amRNSPOLB 001 CRS patent granted in Canada
7th May 20267:00 amRNSAnnual Report & AGM Notice
28th Apr 20267:00 amRNSResults for the year ended 31 December 2025
15th Apr 20267:00 amRNSMHRA grants CTA for the POLB 001 TOPICAL trial
31st Mar 20267:00 amRNSSignificant milestone for Poolbeg's IP portfolio
12th Mar 20267:00 amRNS-RAppointment of Dr Adrian Kilcoyne to SAB
9th Feb 20263:13 pmRNSNotification of Major Holdings
28th Jan 20267:00 amRNSPOLB 001 LPS Challenge Trial Paper Published
27th Jan 20262:30 pmRNSExercise of Options & Total Voting Rights
18th Dec 20257:00 amRNS-RLetter to Shareholders – 2025 a year of progress
8th Dec 20257:00 amRNS-RPOLB 001 to feature in CRS research programme
20th Nov 20257:00 amRNSPOLB 001 European Patent granted
29th Sep 20257:00 amRNSInterim Results for the six months to 30 June 2025
25th Sep 20257:00 amRNSPOLB 001 Phase 2a Trial Update
1st Jul 20254:24 pmRNSNotification of Major Holdings
26th Jun 20257:00 amRNSNotification of Major Holdings
25th Jun 20258:00 amRNSDirector/PDMR Shareholding
23rd Jun 20252:57 pmRNSResults of GM and AGM Meetings
27th May 20257:01 amRNSFDA Orphan Drug Designation granted for POLB 001
27th May 20257:00 amRNSAnnual Report, AGM Notice & Circular
23rd May 20257:00 amRNSResult of upsized oversubscribed BookBuild Offer
22nd May 20251:44 pmRNSIncrease of BookBuild Offer
20th May 202512:26 pmRNSResult of Placing and Notice of General Meeting
20th May 20257:02 amRNSProposed Retail Offer to raise up to £100,000
20th May 20257:01 amRNSProposed Fundraising to raise approximately £4.1M
20th May 20257:00 amRNSResults for the year ended 31 December 2024
27th Mar 20257:00 amRNS-RConference Participation in March & April 2025
20th Mar 20257:00 amRNS-RPOLB 001 Patent Granted in Korea
25th Feb 20258:50 amRNSForm 8.5 (EPT/NON-RI)
24th Feb 20258:48 amRNSForm 8.5 (EPT/NON-RI)
21st Feb 202511:53 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
21st Feb 20257:00 amRNSTermination of proposed combination with HOOKIPA
20th Feb 20258:06 pmGNWHOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
20th Feb 20259:03 amRNSForm 8.5 Poolbeg Pharma Plc
20th Feb 20258:53 amRNSForm 8.5 (EPT/NON-RI)
20th Feb 20257:49 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
19th Feb 202512:35 pmGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
18th Feb 20255:35 pmRNSHolding(s) in Company
18th Feb 20255:04 pmRNSForm 8.3 - Poolbeg Pharma plc
18th Feb 202510:17 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
17th Feb 202510:28 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
14th Feb 202510:25 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
14th Feb 20259:11 amRNSForm 8.5 Poolbeg Pharma Plc
13th Feb 202511:17 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
13th Feb 202510:30 amRNSForm 8.5 Poolbeg Pharma Plc
12th Feb 202510:52 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
12th Feb 20259:08 amRNSForm 8.5 Poolbeg Pharma Plc
11th Feb 20259:46 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.